About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, August 21st, 2015

The QualityStocks
Daily Stock List


EnzymeBioSystems (ENZB)

Greenbackers reported previously on EnzymeBioSystems (ENZB), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

EnzymeBioSystems, a development stage company, concentrates on manufacturing specialty enzymes and enzyme related products. Company Management has been working on developing proprietary Over-the-Counter (OTC) products to be sold under the EnzymeBioSystems label. Founded in 2009, the Company has its corporate headquarters in Las Vegas, Nevada. EnzymeBioSystems’ shares trade on the OTC Bulletin Board.

The Company plans to deploy its enzyme technologies across varied markets, which represent commercial opportunities in helping it build visibility for EnzymeBioSystems. EnzymeBioSystems uses enzyme technologies to develop solutions for a wide assortment of applications within the specialty chemical industry. These markets are mostly served by a small number of large, well-established businesses and research university centers.  

EnzymeBioSystems’ intention is to work collaboratively with those industrial companies to develop differentiated, high performance enzyme solutions for its target markets, and to take advantage of its well-developed distribution capabilities to better exploit commercial opportunities. The Company’s enzyme technology will link with development of new commercial biological active compounds. EnzymeBioSystems’ hope is that it can develop specialty enzymes to eradicate the side effects and toxicity of the new commercial developed products.

EnzymeBioSystems’ foresees its two areas of business opportunity, which include buying raw materials to produce specialty enzymes in the Company’s lab facility and offer these products for sale to research facilities and pharmaceutical companies; and to become a specialty contract manufacture for research universities and pharmaceutical companies that use enzymes in their research programs.

Yesterday, EnzymeBioSystems announced that while it continues its early-stage research to obtain an Investigational New Drug Application for methyl amooranin, a product for the prevention of breast cancer, Company management is also pursuing other opportunities. The Company indicated that there are several ideas in process, and that Management has not limited itself to any particular OTC product idea. This includes sleep remedies and also skin care products.

EnzymeBioSystems (ENZB), closed Friday's trading session at $2.20, up 0.92%, on 102,316 volume with 61 trades. The average volume for the last 60 days is 12,604 and the stock's 52-week low/high is $0.50/$3.90.

InSite Vision, Inc. (INSV)

Penny Performers, StockEgg, and Standout Stocks reported earlier on InSite Vision, Inc. (INSV), and we choose to highlight the Company today, here at the QualityStocks Daily Newsletter.

InSite Vision, Inc. is advancing new specialty ophthalmologic products for treatment of diseases affecting the front and back of the eye. The Company has a proprietary portfolio of clinical-stage product candidates. InSite develops novel ophthalmic products designed to treat a growing range of common eye problems. These include ocular infection, pain and inflammation in ocular surgery, as well as glaucoma. InSite Vision has its corporate headquarters in Alameda, California.

The Company has two commercial products based on its pioneering DuraSite® platform approved for the treatment of bacterial eye infections. One is AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Akorn, Inc. The other is Besivance® (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch + Lomb, a wholly-owned subsidiary of Valeant Pharmaceuticals International.

InSite Vision’s intention is to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in 2016 for the commercial approval by the FDA of DexaSite™ for the treatment of blepharitis. InSite’s AzaSite Plus™ is advancing through Phase 3 clinical studies for the treatment of eye infections, and ISV-101 is in Phase 1/2 clinical development for dry-eye disease and inflammation.

The DuraSite system can be customized to deliver a wide spectrum of potential drug agents. DuraSite is a drug delivery vehicle. It stabilizes small molecules in a polymeric mucoadhesive matrix. The topical ophthalmic solution can be described as a gel forming drop, which extends the residence time of the drug relative to conventional eye drops.

InSite Vision has completed the submission to the FDA of the NDA of BromSite™ for the treatment of inflammation and prevention of pain in cataract surgery. The Company is seeking marketing approval of BromSite™ in the U.S.

The filing of the BromSite™ NDA satisfies InSite Vision's obligation under its recently announced merger agreement with QLT, Inc. The merger transaction has been unanimously approved by the Boards of both companies. It is subject to the approval of InSite Vision shareholders.

This week, InSite Vision announced that the FDA, in a Day-74 letter, has accepted for review the Company’s NDA for BromSite™ (0.075% bromfenac). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of April 10, 2016. InSite Vision is seeking FDA approval for BromSite in the treatment of inflammation and prevention of ocular pain in the post-cataract surgery setting. BromSite has a long patent life extending to August 2029.

Today, InSite Vision announced that its Board concluded that the previously announced unsolicited offer from a multi-national pharmaceutical company  to acquire InSite for $0.25 per share in an all-cash transaction constitutes a “Company Superior Proposal” as defined in InSite Vision’s previously announced definitive agreement with QLT, Inc. dated as of June 8, 2015, as amended. Under the terms of the QLT merger agreement, QLT would acquire InSite Vision in an all-stock transaction; shareholders of InSite will receive 0.048 QLT shares for each InSite Vision share they hold.

InSite Vision, Inc. (INSV), closed Friday's trading session at $0.2401, up 11.67%, on 2,266,878 volume with 143 trades. The average volume for the last 60 days is 278,290 and the stock's 52-week low/high is $0.1201/$0.36.

Elite Pharmaceuticals, Inc. (ELTP)

Top Stock Picks, Stock Analyzer, PennyStocks24, Pumps and Dumps, Planet Penny Stocks, Buzz Stocks, PennyStockProphet, Penny Pick Finders, StockOnion, SecretStockPromo, and Capital Equity Report reported earlier on Elite Pharmaceuticals, Inc. (ELTP), and today we report on the Company, here at the QualityStocks Daily Newsletter.

OTC Bulletin Board-listed Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products.  Additionally, it provides contract manufacturing for Ascend Laboratories (a subsidiary of Alkem Laboratories Ltd.). The Company has also partnered with Epic Pharma (a private pharmaceutical company in Laurelton, New York) for the manufacturing and distribution of approved products pending manufacturing site, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong headquartered company to develop a branded product for the U.S. market and its territories.

The Company owns generic and Over-the-Counter (OTC) products licensed to TAGI Pharma, Epic Pharma, and Valeant Pharmaceuticals International, with eight commercial products now selling, additional approved products pending manufacturing site transfer, and a product under review pending approval by the Food and Drug Administration (FDA). Elite Pharmaceuticals operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, New Jersey, its headquarters.

Elite’s lead pipeline products include abuse resistant opioids using its patented proprietary technology, and a once-daily opioid. They are sustained release oral formulations of opioids for the treatment of chronic pain. These address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse.

Elite announced in July 2014 the first dosing of a pivotal bioequivalence (BE) study in healthy volunteers for ELI-201. This is its twice daily abuse deterrent oxycodone/naltrexone product, using Elite's proprietary pharmacological abuse deterrent technology. The study is an open-label, single-dose, partially-randomized crossover study in healthy adult subjects.

The Company announced in December 2014 successful results from the pivotal BE study for ELI-201. The study demonstrated that Elite’s product is bioequivalent to the branded drug based on pharmacokinetic measures. Final findings of bioequivalence are dependent upon FDA review.

This month, Elite Pharmaceuticals announced the completion of patient enrollment and dosing for the Phase III efficacy trial for ELI-200, an abuse-deterrent opioid product. The design of this Phase III trial is to evaluate the efficacy and safety of abuse deterrent ELI-200 for the treatment of adults with moderate to severe pain following surgery. The study enrolled 163 patients at five clinical sites.

Moreover, this month, Elite announced results for the quarter ended June 30, 2015, the first quarter of the Company’s 2016 fiscal year. Consolidated revenues for the first quarter of Fiscal 2016 were $7.1 million; operating profits totaled $2.5 million. Revenues consisted of $5 million in milestone payments from the ELI-200 license to Epic Pharma and a record $2.1 million produced from product revenue. The milestone payments are the first of a total $15 million in milestones from the ELI-200 licensing agreement.

Elite Pharmaceuticals, Inc. (ELTP), closed Friday's trading session at $0.2075, up 0.97%, on 836,155 volume with 142 trades. The average volume for the last 60 days is 880,767 and the stock's 52-week low/high is $0.1745/$0.389./p>

Bioheart, Inc. (BHRT)

SmallCapVoice, PennyStocks24, Pennybuster, and Energy and Capital reported on Bioheart, Inc. (BHRT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Bioheart, Inc. is an emerging business in the regenerative medicine/cellular therapy industry. It concentrates on the discovery, development, and commercialization of cell based therapeutics, which prevent, treat, or cure disease through repairing and replacing damaged or aged tissue, cells, and organs, and restoring their normal function. The Company’s discoveries include multiple cell therapies in different stages of development that repair damaged hearts of patients suffering from chronic and acute heart damage.

US Stem Cell Training (SCT) and Vetbiologics (VBI) are operating divisions of Bioheart. US Stem Cell Clinic, LLC (SCC) is a partially-owned investment of Bioheart. Bioheart lists on the OTC Markets Group’s OTCQB. Bioheart is headquartered in Sunrise, Florida.

Bioheart’s business includes the development of proprietary cell therapy products and revenue generating physician and patient based regenerative medicine/cell therapy training services. Its business also includes cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic.

US Stem Cell Training (SCT) is a content developer of regenerative medicine/cell therapy informational and training materials for physicians and patients. Furthermore, SCT provides in-person and online training courses. SCT also provides hands-on clinical application training for physicians and health care professionals interested in providing regenerative medicine/cell therapy procedures.

Vetbiologics (VBI) is a veterinary regenerative medicine company. VBI’s commitment is to providing veterinarians with the ability to deliver the highest quality regenerative medicine therapies to dogs, cats and horses.

US Stem Cell Clinic is a physician run regenerative medicine/cell therapy clinic providing cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, as well as degenerative diseases. US Stem Cell Clinic isolates stem cells from bone marrow and adipose tissue and also utilizes platelet rich plasma.

Bioheart announced this past June that it entered into a Letter of Intent (LOI) to acquire Pavillion Scientific, Inc. (Florida) a wholly-owned subsidiary of Pavillion Foods, Inc. (Florida). Pavillion Scientific is the provider of stem cell collection kits to Bioheart and Vetbiologics. Under the terms of the LOI, Pavillion Foods will receive cash, future royalties on a defined number of unit sales, and Bioheart Common Stock warrants to purchase Bioheart Common Stock at a predetermined price. Upon completion of a Definitive Agreement, of which there are no assurances will be completed, Pavillion Scientific will become an operating division of Bioheart.

This week, Bioheart announced its continuing achievements in its first half and Q2 2015 balance sheet positions and performance results from operations. Bioheart President & Chief Executive Officer, Mr. Mike Tomas, stated, "As demonstrated by our first half and second quarter 2015 financial performance improvements, Bioheart continues to improve its top line revenue performance and balance sheet positions."

Bioheart, Inc. (BHRT), closed Friday's trading session at $0.0045, up 2.27%, on 3,299,153 volume with 66 trades. The average volume for the last 60 days is 2,724,598 and the stock's 52-week low/high is $0.004/$0.0275.

Changing Technologies, Inc. (CHGT)

PennyStockRumors.net, StockMarketQuote.us, Fortune Stock Alerts, StockMister, 1-2-3 Stock Alerts, Penny Stock Circle, Joe Penny Stocks, FOX Penny Stocks, Liquid Tycoon, PennyPickAlerts, Super Nova Stock Picks, Penny Stock Pick Alert, Penny Stock Pick Report, Penny Stock Money Train, Super Hot Penny Stocks, RisingPennyStocks, Winning Penny Stock Picks, and WePickPennyStocks reported on Changing Technologies, Inc. (CHGT), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Changing Technologies, Inc. is working to be at the vanguard of the next generation of consumer-based technology. The Houston, Texas-based Company continues to investigate opportunities in the fast-growing 3D printing industry. Changing Technologies focuses on developing inventive concepts to bring to consumers. It developed its goal from the need to explore and offer applications mainly concentrating on improving personal and business productivity and health and fitness monitoring.

Changing Technologies helps its clients’ develop applications. It helps guide them through its ground-breaking “Path Practice” process. This is its tested methodology of helping clients visualize the customer experience, data interactivity, and results expectations.  

Changing Technologies’ new subsidiary is 6th Dimension Technologies. This subsidiary is to pursue additional growth areas and market needs in the growing 3D printing sector.  6th Dimension Technologies’ emphasis is on the first retail micro-manufacturing kiosk. It has its state-of-the art, on-demand retail model for 3D printing at www.6D3D.com. The website will feature a wide array of 3D printable projects created by design engineers.

Changing Technologies continues to develop pioneering new retail 3D printing strategies. It is developing an online 3D printing portal built by interactive software developer Advarion, Inc. for 6th Dimension Technologies (6D3D). It will give users the ability to search its database for printable 3D models and purchase them from the site. It will also provide original equipment manufacturer (OEM) replacement-part manufacturing and licensing opportunities for game and animation developers.

Changing Technologies is looking to foster a worldwide online community of 3D printing users and services. Its online Portal services will be a user access point to the Company’s database of 3D printable designs, where users’ can share their creations. Its forthcoming Portal advances its role as a technological and educational expert in 3D printing. The new Portal will field user questions, test new 3D printing equipment, host webinars, and serve as the number-one educational resource for 3D printing.

Yesterday, Changing Technologies announced that it is now in discussions to design a set of customized headrests for patients undergoing Magnetic Resonance Imaging (MRI) testing at a Houston, Texas-area cancer clinic. The proposed work would continue a series of recent 3D design and printing projects for Changing Technologies as it seeks to increase its revenue stream.

Changing Technologies, Inc. (CHGT), closed Friday's trading session at $0.1294, up 17.64%, on 254,773 volume with 64 trades. The average volume for the last 60 days is 151,113 and the stock's 52-week low/high is $0.07/$2.85.


The QualityStocks
Company Corner


Giggles N' Hugs, Inc. (GIGL)

The QualityStocks Daily Newsletter would like to spotlight Giggles N' Hugs, Inc. (GIGL). Today, Giggles N' Hugs, Inc. closed trading at $0.2051, up 13.31%, on 44,633 volume with 19 trades. The stock’s average daily volume over the past 60 days is 26,644, and its 52-week low/high is $0.101/$0.64.

Los Angeles-based Giggles N' Hugs, Inc. (GIGL) is a first-of-its-kind, award-winning family restaurant and play space that combines organic gourmet food with the play elements for children in a 2500-square-foot play space in the middle of the restaurant. The concept is similar to Chuck E. Cheese, but offers a unique healthier, high-end version for health conscious parents and families. Parents eat and relax while the kids have an incredible time playing in the custom-made play area with giant climbers, dragons, castles, pirate ships slides and swings and a multitude of other toys.

In addition to nightly shows and concerts, every 30 minutes Giggles N' Hugs provides an activity such as face painting, disco dance parties, karaoke, games, arts and crafts, and much more. Giggles N' Hugs has been voted the No. 1 family restaurant, No. 1 birthday party place, and the No. 1 indoor play space in all of Los Angeles, and has attracted a star-studded list of customers including Sandra Bullock, Heidi Klum, Jessica Alba, Halle Berry, Jennifer Garner and Ben Affleck, Denis Quaid, Mark Whalberg, Adam Sandler, Dustin Hoffman and many more.

Revenue is derived from several sources, including food and beverage sales, beer and wine, birthday parties (40%), admission and membership fees to play, along with retail sales. These revenue-generating locations are also highly sought-after tenants. The company currently has three locations in the top premier malls around Los Angeles; four of the largest mall owners in the country are giving Giggles N' Hugs up to 75% discounts on rent and providing upward of $700,000 of upfront cash for each location to get Giggles N' Hugs into their malls around the country.

Growth and recognition of this caliber are driven by a very powerful management team. Giggles N' Hugs President John Kaufman was the COO at California Pizza Kitchen when the founders had just two locations. Joined by Giggles N' Hugs' CFO Phillip Gay, who at the time was CFO of California Kitchen, Kaufman grew the company from two to more than 100 locations – at which time it was bought by Pepsi Co. Kaufman was recruited as president of Koo Koo Roo Chicken, one of the fastest growing fast-casual concepts on the west coast, while Gay joined Wolfgang Puck Restaurants group as CFO, eventually becoming the CEO.

Giggles N' Hugs was founded as a truly "kid friendly" establishment catered specifically to the size, interests, and nutrition needs of children. Since opening its first Giggles N' Hugs in 2009, the company has received a steady stream of interest from more than 300 interested parties looking to expand the concept – via franchise or master licenses – in the U.S. as well globally in countries such as Germany, England, Dubai, Russia, Colombia, Australia , Singapore, Turkey, among the many more. Disclaimer

Giggles N' Hugs, Inc. Company Blog

Giggles N' Hugs, Inc. News:

Giggles Ní Hugs Advances Negotiations with largest National Mall Owners

Interest in Giggles Ní Hugs Franchise Opportunities Continues to Grow

Giggles N' Hugs, Inc. (GIGL) CEO Featured in Exclusive QualityStocks Interview

Growblox Sciences, Inc. (GBLX)

The QualityStocks Daily Newsletter would like to spotlight Growblox Sciences, Inc. (GBLX). Today, Growblox Sciences, Inc. closed trading at $0.30, up 3.45%, on 54,724 volume with 17 trades. The stock’s average daily volume over the past 60 days is 64,899, and its 52-week low/high is $0.151/$1.51.

Growblox Sciences, Inc. (GBLX), a biopharmaceutical research and development company, is focused on creating safe, standardized pharmaceutical-grade cannabis-based therapies for various medical conditions. The company is pioneering technology, industry-leading processes, and a big data-driven clinical research and development algorithm to bring relief to patients in communities across the country.

The company’s GrowBLOX technology suite includes the TissueBLOX, GrowBLOX, and CureBLOX equipment. Together, these components provide unparalleled control and monitoring of cannabis cultivation throughout the plant's life-cycle. These patent pending processes were designed to produce a safe and consistent cannabis product under cGMP guidelines. Utilizing a computer-regulated system that optimizes the nutrients, water, temperature, and gas levels, the GrowBLOX suite produces cannabis with more active ingredients per pound than traditional cultivation methods.

Also, based on an analysis of preclinical and clinical data from thousands of peer-reviewed studies, Growblox Sciences has identified the most effective profiles of cannabinoids and terpenes for the treatment of conditions within seven therapeutic categories. As a result of this extensive research and the analysis of the active ingredient profiles of 30,000 Cannabis strains in conjunction with a major testing lab, the company will be able to provide patients with natural cannabis strains containing the ideal ratios for treating specific diseases or symptoms.

Another significant advantage held by the company stems from an accelerated drug development program to finish in 3-5 years instead of the 15-20 years typically seen in traditional pharmaceutical development programs. Armed with an intellectual property strategy that takes full advantage of the design of the GrowBLOX technology suite and protects the valuable foundation laid, Growblox Sciences has positioned itself well for long-term success in the burgeoning cannabis space. Disclaimer

Growblox Sciences, Inc. Company Blog

Growblox Sciences, Inc. News:

GrowBLOX Sciences is Making Big Moves in Anticipation of Opening Nevada Cultivation Facility

GrowBLOX Receives Funding to Complete Construction of Nevada Cultivation Facility

GrowBLOX Announces Deployment of Commercial Units

Loans4Less.com, Inc. (LFLS)

The QualityStocks Daily Newsletter would like to spotlight Loans4Less.com, Inc. (LFLS). Today, Loans4Less.com, Inc. closed trading at $0.25, up 66.67%, on 500 volume with 1 trade. The stock’s average daily volume over the past 60 days is 894, and its 52-week low/high is $0.0248/$0.25.

Loans4Less.com, Inc. (LFLS) is an online mortgage broker which matches qualified individuals seeking mortgage loans with suitable lenders who offer the company a competitive wholesale lending program. Maintaining an A+ TrustLink rating with the Better Business Bureau, the company provides competitive rates, terms, costs, daily updates, extensive market information, and trusted first-class service to the public.

Leveraging its portfolio of 62 different web domains, Loans4Less.com is focused on developing a national consumer platform for conforming residential mortgage programs and implementation of other consumer loan programs via operating providers. The company's expansion strategy includes rapidly growing revenues through strategic and cost-effective advertising, licensing, and/or third party agreements that build national recognition of the Loans4Less® brand.

The management team has accumulated many years of experience in the real estate and financial services sectors. This combination of expertise provides the knowledge and foresight necessary to get the best results for the company and their thousands of loyal clients. The team skillfully navigated through the credit crisis that destroyed much of their competition, putting the company in a stronger position to increase market share.

Loans4Less.com is not exposed to the risks and/or problems that are associated with sub-prime lending. Having never defaulted on an obligation or been involved in any litigation, the company is poised for rapid growth in today's low interest rate environment with its industry leading reputation and well established relationships with respected lenders. Disclaimer

Loans4Less.com, Inc. Company Blog

Loans4Less.com, Inc. News:

LOANS4LESS.COM Enters into an Acquisition Agreement with 321LEND

Loans4Less.com, Inc. Enters into an Investment Banking Agreement with WestPark Capital, Inc. and Seeks Bank Strategic Partner for National Mortgage Broker Origination and Brand Exposure Opportunity

Loans4Less.com Seeks a Merger, Joint Venture Partner and/or Investor for National Loan Origination and Brand Exposure Opportunity

Galenfeha, Inc. (GLFH)

The QualityStocks Daily Newsletter would like to spotlight Galenfeha, Inc. (GLFH). Today, Galenfeha, Inc. closed trading at $0.20, up 17.44%, on 22,651 volume with 10 trades. The stock’s average daily volume over the past 60 days is 63,870, and its 52-week low/high is $0.1011/$4.00.

Galenfeha, Inc. (GLFH) is an engineering, product development, and manufacturing company that provides innovative solutions for oil and natural gas production, as well as stored energy products across a number of different industries. The company provides these products and services through its stored energy and oil & gas division.

Through its stored energy division, Galenfeha offers one of the most powerful, environmentally friendly battery systems in the market. The batteries have onboard computers, are inherently safe, internally temperature regulated, have optional GPS monitoring capabilities, offer significant weight reduction of up to 50%, and are engineered specifically for each type of application. Features include 100% “green” chemistry, RoHS compliancy, and active short circuit protection control.

Through its oil and gas division, the company offers chemical injection pumps that merge the perceived benefits of a hybrid, electric over pneumatic system. Galenfeha management believes the combination of the two parameter control systems represents a measurable shift in efficiency, reliability, cost management, and profitability to individual well locations as well as entire production fields. The combined technologies have demonstrated increased chemical injection accuracy, reducing chemical contamination in the production process while controlling cost and waste.

The company’s unwavering dedication is to continuously develop products that perform better than conventional solutions while also reducing environmental impact. Leveraging the management team’s wealth of resources and relationships, Galenfeha is well positioned for continued growth as the company aims to expand in both the stored energy and oil & gas industries. Disclaimer

Galenfeha, Inc. Company Blog

Galenfeha, Inc. News:

Galenfeha, Inc. Products Offered by Leading Power and Automation Company

Galenfeha Stored Energy Solutions Enters Aviation Industry

Galenfeha Broadens Oil and Gas Industry Penetration

Star Mountain Resources, Inc. (SMRS)

The QualityStocks Daily Newsletter would like to spotlight Star Mountain Resources, Inc. (SMRS). Today, Star Mountain Resources, Inc. closed trading at $1.05, even for the day. The stock’s average daily volume over the past 60 days is 3,491, and its 52-week low/high is $0.30/$1.40.

Star Mountain Resources, Inc. (SMRS), a minerals exploration company, is focused on acquiring and consolidating mining claims, mineral leases, producing mines, and historic mines with production and future growth potential identified through exploration efforts. The company's operations are currently focused on the initiation, production and expansion of acquired mineral resources in the Star Mountain Mining District, Beaver County, Utah and turning them into producing assets.

Comprised of 2,320 acres, the company's Star Mountain/Chopar Mine project consists of 116 lode-mining claims and four metalliferous mineral lease sections located in the Star Mountain range, Star Mining District, in Beaver County, Utah, approximately five miles west of Milford, Utah. Exploration activities to date include geological analysis, and a limited reverse circulation & core drilling program.

The Star Mountain Mining District, which is dotted with historic mines dating back to the late 1800s, has a long and storied history within the mining industry. The company believes that the application of modern exploration tools will reveal additional resources that were previously unattainable. Leveraging the region's mild climate and accessibility to nearby rail lines and roads, management will look to translate this potential into sustainable returns in the years to come.

Star Mountain Resources has adopted a discovery-based business model to grow its industry presence in the future. The company plans to thoroughly explore and initially develop its leasehold before seeking senior industry partners to assist in the capital-intensive development and operation phases. Building on this strategy, Star Mountain Resources will also continue to seek quality projects that can be evaluated on their own technical and financial merit. Disclaimer

Star Mountain Resources, Inc. Company Blog

Star Mountain Resources, Inc. News:

Star Mountain Resources Inc. (SMRS) Pursues Acquisition Opportunities in North American Mining Sector

Star Mountain Resources Inc. Pursuing Acquisition of North American Base Metal Mine

StockNewsNow.com Publishes New SNN Q&A with Star Mountain Resources Inc.


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters








By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251